Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year results.
Atrial shunt
HFpEF
Heart failure
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
12 Apr 2024
12 Apr 2024
Historique:
revised:
27
03
2024
received:
14
03
2024
accepted:
30
03
2024
medline:
12
4
2024
pubmed:
12
4
2024
entrez:
12
4
2024
Statut:
aheadofprint
Résumé
Patients with heart failure and mildly reduced or preserved ejection fraction have limited therapeutic options. The ALT-FLOW Early Feasibility Study evaluated safety, haemodynamics and outcomes for the APTURE transcatheter shunt system, a novel left atrium to coronary sinus shunt in these patients. Safety and shunt implantation success was evaluated for all 116 enrolled patients. An analysis population of implanted patients with a left ventricular ejection fraction (LVEF) >40% (n = 95) was chosen to assess efficacy via paired comparison between baseline and follow-up haemodynamic (3 and 6 months), and echocardiographic, clinical and functional outcomes (6 months and 1 year). Health status and quality of life outcomes were assessed using the Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS). The primary safety endpoint, major adverse cardiac, cerebral, and renal events, and reintervention through 30 days, occurred in 3/116 patients (2.6%). All implanted shunts were patent at 1 year. In patients with LVEF >40%, the mean (95% confidence interval) reduction in exercise pulmonary capillary wedge pressure (PCWP) at 20 W was -5.7 (-8.6, -2.9) mmHg at 6 months (p < 0.001). At baseline, 8% had New York Heart Association class I-II status and improved to 68% at 1 year (p < 0.001). KCCQ-OSS at baseline was 39 (35, 43) and improved at 6 months and 1 year by 25 (20-30) and 27 (22-32) points, respectively (both p < 0.0001). No adverse changes in haemodynamic and echocardiographic indices of right heart function were observed at 1 year. Overall, the reduction in PCWP at 20 W and improvement in KCCQ-OSS in multiple subgroups were consistent with those observed for the entire population. In patients with heart failure and LVEF >40%, the APTURE shunt demonstrated an acceptable safety profile with significant sustained improvements in haemodynamic and patient-centred outcomes, underscoring the need for further evaluation of the APTURE shunt in a randomized trial.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Edwards Lifesciences
Informations de copyright
© 2024 European Society of Cardiology.
Références
SOLVD Investigators; Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325(5):293–302. https://doi.org/10.1056/NEJM199108013250501
The Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): A randomised trial. Lancet 1999;353:9–13. https://doi.org/10.1016/S0140‐6736(98)11181‐9
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR‐Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–1424. https://doi.org/10.1056/NEJMoa2022190
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM‐HF Investigators and Committees. Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717. https://doi.org/10.1056/NEJM199909023411001
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al.; EMPHASIS‐HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21. https://doi.org/10.1056/NEJMoa1009492
D'Amario D, Rodolico D, Delvinioti A, Laborante R, Iacomini C, Masciocchi C, et al. Eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge. J Am Heart Assoc 2023;12:e029071. https://doi.org/10.1161/JAHA.122.029071
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e876–e894. https://doi.org/10.1161/CIR.0000000000001062
Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence‐based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861–870. https://doi.org/10.1161/CIRCULATIONAHA.118.034646
Simard T, Labinaz M, Zahr F, Nazer B, Gray W, Hermiller J, et al. Percutaneous atriotomy for levoatrial‐to‐coronary sinus shunting in symptomatic heart failure: First‐in‐human experience. JACC Cardiovasc Interv 2020;13:1236–1247. https://doi.org/10.1016/j.jcin.2020.02.022
Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, et al.; REDUCE LAP‐HF II Investigators. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP‐HF II): A randomised, multicentre, blinded, sham‐controlled trial. Lancet 2022;399:1130–1140. https://doi.org/10.1016/S0140‐6736(22)00016‐2
Feldman T, Mauri L, Kahwash R, Litwin S, Ricciardi MJ, van der Harst P, et al.; REDUCE LAP‐HF I Investigators and Study Coordinators. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP‐HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A phase 2, randomized, sham‐controlled trial. Circulation 2018;137:364–375. https://doi.org/10.1161/CIRCULATIONAHA.117.032094
Kaye DM, Hasenfuss G, Neuzil P, Post MC, Doughty R, Trochu JN, et al. One‐year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circ Heart Fail 2016;9:e003662. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003662
Malek F, Neuzil P, Gustafsson F, Kaye DM, Walton A, Mates M, et al. Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. Int J Cardiol 2015;187:227–228. https://doi.org/10.1016/j.ijcard.2015.03.198
Shah SJ, Feldman T, Ricciardi MJ, Kahwash R, Lilly S, Litwin S, et al. One‐year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP‐HF I) trial: A randomized clinical trial. JAMA Cardiol 2018;3:968–977. https://doi.org/10.1001/jamacardio.2018.2936
Sondergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M, et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail 2014;16:796–801. https://doi.org/10.1002/ejhf.111
Paitazoglou C, Bergmann MW, Ozdemir R, Pfister R, Bartunek J, Kilic T, et al.; AFR‐PRELIEVE Investigators. One‐year results of the first‐in‐man study investigating the atrial flow regulator for left atrial shunting in symptomatic heart failure patients: The PRELIEVE study. Eur J Heart Fail 2021;23:800–810. https://doi.org/10.1002/ejhf.2119
Paitazoglou C, Ozdemir R, Pfister R, Bergmann MW, Bartunek J, Kilic T, et al. The AFR‐PRELIEVE trial: A prospective, non‐randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction. EuroIntervention 2019;15:403–410. https://doi.org/10.4244/EIJ‐D‐19‐00342
Hibbert B, Zahr F, Simard T, Labinaz M, Nazer B, Sorajja P, et al.; ALT FLOW Investigators. Left atrial to coronary sinus shunting for treatment of symptomatic heart failure. JACC Cardiovasc Interv 2023;16:1369–1380. https://doi.org/10.1016/j.jcin.2023.03.012
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al.; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023;61:2200879. https://doi.org/10.1183/13993003.00879‐2022
Guazzi M, Dixon D, Labate V, Beussink‐Nelson L, Bandera F, Cuttica MJ, et al. RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: Stratification of clinical phenotypes and outcomes. JACC Cardiovasc Imaging 2017;10:1211–1221. https://doi.org/10.1016/j.jcmg.2016.12.024
Hasenfuss G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, et al.; REDUCE LAP‐HF Study Investigators. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP‐HF): A multicentre, open‐label, single‐arm, phase 1 trial. Lancet 2016;387:1298–1304. https://doi.org/10.1016/S0140‐6736(16)00704‐2
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA‐HF trial. Circulation 2020;141:90–99. https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial. Nat Med 2021;27:1954–1960. https://doi.org/10.1038/s41591‐021‐01536‐x